**Supplementary table 1. Baseline medication use in all study patients**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  |  |  | PlGF  |  |
|  |  | All participants |  | <19.6 pg/mL |  | ≥19.6 pg/mL | P |
| ***Number of Patients*** |  | 205 |  | 102 |  | 103 |  |
| ***Medication, n (%)*** |  |  |  |  |  |  |  |
| Renin-angiotensin inhibitors |  | 115 (56) |  | 63 (62) |  | 52 (50) | 0.2 |
| Calcium channel blockers |  | 114 (56) |  | 67 (66) |  | 47 (46) | < 0.001 |
| β blockers |  | 38 (19) |  | 15 (15) |  | 23 (22) | 0.16 |
| Lipid-lowering agents |  | 35 (17) |  | 14 (14) |  | 21 (20) | 0.2 |
| Antiplatelet agents |  | 94 (46) |  | 35 (34) |  | 59 (57) | < 0.001 |
| Diuretics |  | 61 (30) |  | 38 (37) |  | 23 (22) | 0.02 |
|  |  |  |  |  |  |  |  |

**Supplementary table 2. Univariate linear regression analysis of variables associated with angiogenic factors**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Variables | PlGF |  |  | VEGF |  |
|  | Coefficient (95% CI) | *P*  |  | Coefficient (95% CI) | *P*  |
| ***Clinical data*** |  |  |  |  |  |
| Age (per 10-year increase) | 0.22 (−0.9 to 1.3) | 0.69 |  | 11 (−26 to 47) | 0.57 |
| Gender, female (versus male) | 0.30 (−2.3 to 2.9) | 0.82 |  | 46 (−39 to 131) | 0.29 |
| Dialysis vintage, ≥36 months (versus <36 months) | 3.7 (1.3 to 6.2) | 0.003 |  | −34 (−116 to 49) | 0.42 |
| Diabetes  | 0.74 (−1.7 to 3.2) | 0.56 |  | −41 (−123 to 42) | 0.33 |
| Hypertension  | −0.75 (−4.3 to 2.8) | 0.67 |  | 37 (−79 to 153) | 0.53 |
| Dyslipidemia  | 1.54 (−1.3 to 4.4) | 0.28 |  | −0.52 (−94 to 93) | 0.99 |
| Smoking  | 0.82 (−1.7 to 3.3) | 0.51 |  | −13 (−95 to 69) | 0.28 |
| History of CAD | 3.6 (0.9 to 6.3) | 0.01 |  | −69 (−161 to 22) | 0.14 |
| History of stroke | 0.50 (−3.1 to 4.1) | 0.78 |  | 33 (−84 to 151) | 0.58 |
| Systolic BP (per 10 mmHg increase) | −0.65 (−1.1 to 0.2) | 0.005 |  | −13 (−28 to 1.8) | 0.08 |
| Diastolic BP (per 10 mmHg increase) | −1.0 (−1.9 to 0.2) | 0.02 |  | −13 (−42 to 16) | 0.39 |
| ***Laboratory data*** |  |  |  |  |  |
| Hemoglobin, ≥10 mg/dL (versus <10 mg/dL) | 0.22 (−2.9 to 3.3) | 0.91 |  | −57 (−159 to 45) | 0.27 |
| Albumin, <3.0 g/dL (versus ≤3.0 g/dL) | 1.8 (−1.4 to 4.9) | 0.27 |  | 285 (188 to 382) | < 0.001 |
| HbA1c, ≥6.5% (versus <6.5%) | 0.18 (−2.9 to 3.3) | 0.91 |  | −57 (−159 to 45) | 0.27 |
| Blood Urea nitrogen, ≥60 mg/dL (versus <60 mg/dL) | −2.9 (−5.5 to −0.2) | 0.03 |  | 4.8 (−84 to 94) | 0.91 |
| Creatinine, ≥7.0 mg/dL (versus <7.0 mg/dL) | −0.38 (−3.0 to 2.2) | 0.77 |  | 97 (12 to 183) | 0.27 |
| LDL cholesterol, ≥120 mg/dL (versus <120 mg/dL) |  −2.0 (−4.9 to 0.8) | 0.16 |  | −29 (−123 to 66) | 0.55 |
| HDL cholesterol, <40 mg/dL (versus ≥40 mg/dL) | 4.0 (1.4 to 6.6) | 0.002 |  | 34 (−54 to 122) | 0.44 |
| Triglycerides, ≥150 mg/dL (versus <150 mg/dL) | 0.99 (−2.0 to 4.0) | 0.52 |  | −26 (−127 to 74) | 0.60 |
| Calcium, ≥10 mg/dL (versus <10 mg/dL) | 1.6 (−1.3 to 4.6) | 0.28 |  | −8.6 (−108 to 91) | 0.87 |
| Phosphorus, ≥6.0 mg/dL (versus <6.0 mg/dL) | −1.3 (−2.9 to 3.3) | 0.91 |  | −57 (−159 to 45) | 0.27 |
| BNP, ≥322.2 pg/ml (versus <322.2 pg/ml) | 1.4 (−1.1 to 3.9) | 0.28 |  | 38 (-44 to 121) | 0.36 |
| VEGF, ≥273 pg/mL (versus <273 pg/mL) | 1.6 (−0.9 to 4.1) | 0.20 |  |  |  |
| PlGF, ≥19.6 pg/mL (versus <19.6 pg/mL) |  |  |  | 25 (−57 to 107) | 0.55 |

CI, confidence interval; PlGF, placental growth factor; VEGF, vascular endothelial growth factor; CAD, coronary artery disease; BP, blood pressure; HbA1c, glycated hemoglobin; LDL, low density lipoprotein; HDL, high density lipoprotein; BNP, brain natriuretic peptide.